Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates February 27, 2023 — 05:35 pm EST Written by Zacks Equity Research for Zacks-> Si-Bone (SIBN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.81%. A quarter ago, it was expected that this medical device maker would post a loss of $0.45 per share when it actually produced a loss of $0.41, delivering a surprise of 8.89%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Si-Bone, which belongs to the Zacks Medical - Instruments industry, posted revenues of $31.95 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 0.48%. This compares to year-ago revenues of $25.23 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Si-Bone shares have added about 25.2% since the beginning of the year versus the S&P 500's gain of 3.4%.What's Next for Si-Bone?While Si-Bone has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Si-Bone: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.46 on $26.6 million in revenues for the coming quarter and -$1.68 on $124.4 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Another stock from the same industry, Silk Road Medical (SILK), has yet to report results for the quarter ended December 2022. The results are expected to be released on February 28.This medical device maker is expected to post quarterly loss of $0.37 per share in its upcoming report, which represents a year-over-year change of +11.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.Silk Road Medical's revenues are expected to be $37.31 million, up 32% from the year-ago quarter. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportSiBone (SIBN) : Free Stock Analysis ReportSilk Road Medical, Inc. (SILK) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags StocksInvesting Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. More articles by this source-> Stocks mentioned SIBN More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.